Clinical data
ATC code None
CAS Number 308239-86-3
PubChem (CID) 9885841
ChemSpider 8061514
Chemical and physical data
Formula C17H17ClN6O2
Molar mass 372.809 g/mol
3D model (Jmol) Interactive image

EVT-201 is a benzodiazepine derivative drug and partial positive allosteric modulator of the benzodiazepine site of the GABAA receptor.[1] It has 2–4-fold higher functional affinity for the α1 subunit relative to the α2, α3, and α5 subunits and significantly less intrinsic activity in comparison to currently-marketed benzodiazepines and the Z-drugs.[2] Despite the lower efficacy, EVT-201 still shows effectiveness in the treatment of insomnia, and it is thought that the lower efficacy may result in fewer side effects, such as motor incoordination.[2] The drug was originally developed by Roche, based on preclinical data, as a non-sedating anxiolytic, but was found to produce sedation in humans in phase I clinical trials. For this reason, it was subsequently licensed to Evotec, which is now developing it for the treatment of insomnia.[2] As of 2007, EVT-201 has completed phase II clinical trials for this indication, with positive findings reported.[3] As of August, 2015, Phase II development is ongoing in China.[4]


  1. Christian Guilleminault (2010). Sleep Medicine. Elsevier Health Sciences. pp. 574–. ISBN 1-4377-1836-1.
  2. 1 2 3 Jaime M. Monti; Seithikurippu Ratnas Pandi-Perumal; Hanns Möhler (28 September 2010). GABA and Sleep: Molecular, Functional and Clinical Aspects. Springer Science & Business Media. pp. 50–51. ISBN 978-3-0346-0226-6.
  3. Jack W. Plunkett (September 2007). Plunkett's Biotech & Genetics Industry Almanac 2008: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies. Plunkett Research, Ltd. pp. 311–. ISBN 978-1-59392-087-6.
  4. "Drug Profile: EVT 201". AdisInsight. Adis International Ltd, part of Springer Science+Business Media. Retrieved 30 November 2015.
This article is issued from Wikipedia - version of the 10/11/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.